Integrated HIV prevention strategy increases PrEP adherence among transgender women

Researchers from the HIV Prevention Trials Network (HPTN) presented results from HPTN 091 (“I Am Study”) at the HIVR4P 2024 conference in Lima, Peru. The study examined the acceptability and feasibility of an integrated multicomponent strategy to enhance daily oral HIV pre-exposure prophylaxis (PrEP) uptake and adherence among transgender women in a randomized immediate versus deferred design.

Bacteria’s “suicidal” immune system boosts antibiotic power against cholera

Bacteria have an immune system that protects them against viruses known as bacteriophages. A research team from the Universities of Tübingen and Würzburg has now

January 19, 2024

Australian life sciences VC Brandon Capital raises $180M for sixth fund

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 4, 2024

Signal: Danaher’s $5.7bn acquisition of Abcam faces stand-off with founder – Pharmaceutical Technology

Abcam was founded in 1998 and has been called the “Amazon of antibodies”. Photo: Shutterstock. Abcam’s $5.7bn acquisition by multi-national conglomerate Danaher may be blocked

September 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.